Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis #ActAgainstAmputation @usc_vascular

Here are the most up-to-date data on the possible association (or not) of SGLT2 inhibitors to diabetes related lower extremity amputation

Conclusions: Overall, there was no consistent evidence of SGLT2i exposure and increased risk of amputation. The increased risk of amputation seen in the large, long-term Canagliflozin Cardiovascular Assessment Study (CANVAS) trial for canagliflozin, and select observational studies, merits continued exploration.